Gengsheng Yu
Jiangmen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Safety of fruquintinib mono- and combo therapy in metastatic colorectal cancer: real-world subgroup analysis from China.
Journal: Future oncology (London, England)
Published: May 28, 2026
HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial.
Journal: Therapeutic advances in medical oncology
Published: January 28, 2026
A Phase II Study of Toripalimab in Combination with Gemcitabine and 5-Fluorouracil as First-Line Therapy for Advanced or Metastatic Biliary Tract Carcinoma.
Journal: Cancers
Published: October 08, 2025
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.
Journal: Therapeutic advances in medical oncology
Published: March 10, 2025
Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial.
Journal: Communications medicine
Published: February 19, 2025
Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 11, 2021
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Journal: Lancet (London, England)
Published: July 15, 2016
Showing 1-8 of 8
Last Updated: 09/26/2026